Rheumatoid Arthritis Awareness
Vibeke Strand, MD
Strand reports serving as a consultant for Abbvie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, ChemoCentryx, Eli Lilly, Genentech/Roche, Gilead, GSK, Horizon, Inmedix, Janssen, Kiniksa, Merck, Novartis, Pfizer, Priovant, Regeneron, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Setpoint, SOFUSA and Sepherix.
VIDEO: What's in the pipeline for RA
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify cperla@healio.com if there are concerns regarding accuracy of the transcription.
One of the nicest ones is Vagus nerve stimulation. Either with an implantable device, which is extremely small, well tolerated and actually can be left in place chronically or with one that is applied, say to the ear, we've seen that patients who've otherwise been not very responsive to current therapies have had some very fast and long-lasting results.
This has also been shown in lupus in a very small number of patients. So, I'm quite interested in this. And I think it appeals to a population of patients who haven't been happy with our current either oral or sub-q therapies.
And of course there's two Anti-GM-CSF monoclonal antibodies Mavrilimumab and Otilimab, and both of them have, have positive studies and are promising, but we'll have to wait and see. Otilimab is in phase 3 against Tofacitinib. So that should be very interesting. And Mavrilimumab has looked promising in GCA. Maybe also it will be in RA.
